Medical News Today1d
Lenacapavir injection lowers HIV risk by 96%
Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...
India Today on MSN1d
New injection reduces risk of HIV infection by 96%: All about it
A new HIV prevention method, a twice-yearly injection of the drug called Lenacapavir, has shown groundbreaking results, ...
HIV prophylactic lenacapavir — very safe and very expensive
Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...
Labroots20h
Twice Yearly Injection 96% Reduces HIV Infection Risk by 96%
A recent phase 3 trial found that twice-yearly injections of Lenacapavir reduce the risk of contracting HIV by 96%. | Drug ...
Interesting Engineering on MSN2d
From chronic to curable: Twice-yearly shot shows near-total HIV eradication
Scientists have developed Lenacapavir, a twice-yearly injection that cuts HIV infection risk by 96% in groundbreaking trials.
Twice-yearly shot could help end AIDS. But will it get to everyone who needs it?
The shot was 100% effective in preventing HIV infections in a study of women, and results published Wednesday show it worked ...
Medscape1d
HIV ‘Game-Changer’ Drug: Is Eastern Europe Missing Out?
In the PURPOSE 2 trial, lenacapavir offered almost complete protection to cisgender men, transgender women, transgender men, ...
Six-Month HIV Prevention Shot Achieves 99% Efficacy in Major Study
Lenacapavir, a new twice-yearly injection, offers 96% HIV prevention efficacy, surpassing daily oral PrEP. For oral ...
HIV Breakthrough as New Injection 89% More Effective Than PrEP
"PrEP reduces the risk of getting HIV from sex by about 99 percent when taken as prescribed. Although there is less ...
GlobalData on MSN6d
Gilead’s twice-yearly lenacapavir shows promise in HIV prevention trial
The Phase III Purpose 2 trial compared the safety and efficacy of twice-yearly subcutaneous lenacapavir for pre-exposure ...